Skip to content

Advertisement

BMC Cancer

What do you think about BMC? Take part in

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

MicroRNA-195 acts as an anti-proliferative miRNA in human melanoma cells by targeting Prohibitin 1

  • Priscila Daniele Ramos Cirilo1, 2, 3,
  • Luciana Nogueira de Sousa Andrade1,
  • Bruna Renata Silva Corrêa2, 4,
  • Mei Qiao2,
  • Tatiane Katsue Furuya1,
  • Roger Chammas1 and
  • Luiz Otavio Ferraz Penalva2Email author
BMC Cancer201717:750

https://doi.org/10.1186/s12885-017-3721-7

Received: 28 December 2016

Accepted: 30 October 2017

Published: 10 November 2017

Back to article

Open Peer Review reports

Pre-publication versions of this article and author comments to reviewers are available by contacting info@biomedcentral.com.

Original Submission
28 Dec 2016 Submitted Original manuscript
13 Feb 2017 Reviewed Reviewer Report - Gennaro Ciliberto
17 Feb 2017 Reviewed Reviewer Report - Laura Gatti
20 Feb 2017 Reviewed Reviewer Report - Monica Rodolfo
15 Jun 2017 Author responded Author comments - Priscila Cirilo
Resubmission - Version 2
15 Jun 2017 Submitted Manuscript version 2
29 Jun 2017 Reviewed Reviewer Report - Laura Gatti
14 Jul 2017 Reviewed Reviewer Report - Monica Rodolfo
14 Aug 2017 Author responded Author comments - Priscila Cirilo
Resubmission - Version 3
14 Aug 2017 Submitted Manuscript version 3
11 Oct 2017 Author responded Author comments - Priscila Cirilo
Resubmission - Version 4
11 Oct 2017 Submitted Manuscript version 4
Publishing
30 Oct 2017 Editorially accepted
10 Nov 2017 Article published 10.1186/s12885-017-3721-7

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article and author comments to reviewers are available by contacting info@biomedcentral.com. All previous versions of the manuscript and all author responses to the reviewers are also available.

You can find further information about the peer review system here.

Authors’ Affiliations

(1)
Instituto do Câncer do Estado de São Paulo, Centro de Investigação Translacional em Oncologia, Laboratório de Oncologia Experimental
(2)
The University of Texas Health Science Center at San Antonio, Children’s Cancer Research Institute
(3)
Instituto Hermes Pardini, Setor de Pesquisa e Desenvolvimento
(4)
Instituto Sírio-Libanês de Ensino e Pesquisa, Centro de Oncologia Molecular

Advertisement